Latest News From "The Pink Sheet" DAILY - Sanofi Leaves Open Possibility Of Acquiring Genzyme

Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely

Sanofi-Aventis is interested in acquiring a company with market cap up to $20 billion, CEO Viehbacher says, leaving open the possibility of acquiring Genzyme.   read more

 

Surrogate Endpoint For Pediatric PAH Gets Advisory Panel OK, But Validation Process Draws Concern

Pfizer can use a hemodynamic endpoint in pediatric trials of Revatio (sildenafil), but FDA's Cardiovascular and Renal Drugs Advisory Committee expresses enough ambiguity to spoil the precedent.   read more

 

AstraZeneca Not Interested In Acquisitions for Scale, Flat Revenues But Growing Margins

Little to say on Brilinta, sales momentum driven by Symbicort, Seroquel and Crestor.   read more

 

Merck Teams Up With Sinopharm On Vaccines As It Gears Up For Gardasil Approval In China

Sinopharm is the largest China-owned pharma and is operated by an agency of the central government in Beijing.   read more

 

Athersys Gets An Efficacy Signal In Phase I Safety Study Of MultiStem In Heart Attack

Patients in a Phase I study of the adult stem cell product showed encouraging improvement in cardiac function, a surprise efficacy signal in addition to a clean safety profile.   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here